Dynavax raises FY23 HEPLISAV-B net product revenue outlook to $200M-$215M

Full year 2023 financial guidance has been revised to consist of the following expectations: Raising HEPLISAV-B net product revenue between approximately $200 – $215 million, compared to the prior range of approximately $165 – $185 million. Reiterating research and development expenses between approximately $55 – $70 million. Reiterating selling, general and administrative expenses between approximately $135 – $155 million.